articleTop 1% cited

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

The Lancet Oncology · 2009 · Vol. 10(5) · pp. 459–466

Roger Stupp✉(University Hospital of Lausanne)Monika E. Hegi(University of Lausanne)Warren Mason(Princess Margaret Cancer Centre)Martin J. van den Bent(Erasmus University Rotterdam)Martin Taphoorn(University Medical Center Utrecht)Robert C. Janzer(University of Lausanne)Samuel K. Ludwin(Queen's University)Anouk Allgeier(European Organisation for Research and Treatment of Cancer)Barbara Fisher(Western University)Karl Bélanger(Hôpital Notre-Dame)Peter HauAlba A. BrandesJohanna M. M. Gijtenbeek(Radboud University Medical Center)Christine Marosi(Medical University of Vienna)Charles J. Vecht(Erasmus University Rotterdam)Karima Mokhtari(Sorbonne Université)Pieter Wesseling(Radboud University Nijmegen)S. Villà(Institut Català d'Oncologia)Elizabeth A. Eisenhauer(Ontario Institute for Cancer Research)Thierry Gorlia(European Organisation for Research and Treatment of Cancer)Michael Weller(University of Tübingen)Denis Lacombe(European Organisation for Research and Treatment of Cancer)J. Gregory Cairncross(University of Calgary)René‐Olivier Mirimanoff(University of Lausanne)

View via DOI Publisher page

Glioma Diagnosis and Treatment Brain Metastases and Treatment Histone Deacetylase Inhibitors ResearchMedicineTemozolomideRadiation therapyConcomitantInternal medicineHazard ratioClinical endpointOncologyAdjuvantCancer

MeSH terms

TemozolomideBrain NeoplasmsCombined Modality TherapyDacarbazineFemaleFollow-Up StudiesGlioblastomaHumansMaleMiddle AgedPrognosisPromoter Regions, GeneticDNA Modification MethylasesSurvival RateSurvival Analysis

Citations

7,709

FWCI

128.20

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Management of glioblastoma: State of the art and future directions